TIGIT/CD155 Axis in HCC: NK Cell Metabolic Reprogramming Study

A research study investigating the TIGIT/CD155 immune checkpoint in hepatocellular carcinoma (HCC). The work, authored by Jiaojie Shu, includes data from an HCC mouse model analyzed via single-cell and bulk RNA sequencing, co-culture systems, and in vivo xenograft models, last updated in May 2026. The findings detail how the axis suppresses NK cell glycolytic metabolism and anti-tumor function via the SHP-2/STAT3/GLUT1 pathway.

Use Cases

• Study NK cell dysfunction in hepatocellular carcinoma based on scRNA-seq and bulk RNA-seq data
• Investigate metabolic reprogramming in immune cells based on glycolytic activity assays (ECAR, glucose uptake, lactate production)
• Analyze the TIGIT/CD155/SHP-2/STAT3/GLUT1 signaling axis based on molecular interaction data (co-IP, western blot, immunofluorescence)
• Evaluate the effects of TIGIT blockade on tumor growth and NK cell function based on in vivo xenograft model results

Strengths

• Dataset is openly licensed under CC-BY-4.0.
• The description provides a detailed methodological breakdown of in vitro and in vivo experiments.
• Includes multi-omics data from single-cell RNA sequencing and bulk RNA sequencing.

Limitations

• The primary data file is a 12.8 KB DOCX document, suggesting the dataset is likely a summary or manuscript rather than raw experimental data.
• Column-level documentation and sample data are unavailable, making direct analysis impossible without the underlying data files.
• Row count and specific data structure are unknown, limiting suitability assessment for computational tasks.

Provenance

Source

figshare

Collection Method

Data was generated from an HCC mouse model, single-cell and bulk RNA sequencing, co-culture systems, and molecular assays.

Freshness

Last updated 2026-05-01 05:28:11